Johns Hopkins University School of Medicine (JHU) and Clearmind Medicine will be collaborating on research to investigate the use of a novel psychoactive molecule to treat...
A study by researchers at NYU Grossman School of Medicine has found that two doses of psilocybin reduced heavy drinking by 83 per cent when combined...
B.More has submitted an Investigational New Drug (IND) application for its Psilocybin Alcohol Use Disorder Programme.
A new MoU will explore a partnership to utilise MDMA-assisted psychotherapy for the treatment of Alcohol Use Disorder (AUD) in Europe.
The world’s first controlled study exploring the use of ketamine-assisted psychotherapy for the treatment of alcohol use disorder (AUD) has shown positive results.
Co-founder and CEO Anthony Tennyson spoke to Psychedelic Health about Awakn’s mission to transform mental health and addiction care through psychedelics.
Cybin is to meet with the UK’s Medical and Healthcare Products Regulatory Agency (MHRA) to discuss its lead psychedelic candidate CYB003 as a treatment for Major...
Clearmind Medicine has signed an R&D agreement with Bar-Ilan University to explore the efficacy of its compound for the treatment of addiction.
Awakn has signed a Memorandum of Understanding (MOU) with the Devon Partnership NHS Trust and the University of Exeter to increase access to psychedelic-assisted therapy for...
Kicking off the Microdose Wonderland conference in Miami, Cybin Inc announced it will be moving its psilocybin analogue – CYB003 – into clinical trials.
